

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 487/04, A61K 31/55, C07D 495/14, 487/14, 498/04, 471/04, 491/147 // (C07D 487/04, 235:00, 223:00) (C07D 495/14, 333:00, 235:00, 223:00) (C07D 487/14, 235:00, 223:00, 209:00) (C07D 498/04, 267:00, 235:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/34897</p> <p>(43) International Publication Date: 25 September 1997 (25.09.97)</p>
<p>(21) International Application Number: PCT/EP97/01264</p> <p>(22) International Filing Date: 11 March 1997 (11.03.97)</p> <p>(30) Priority Data: 96200755.5 19 March 1996 (19.03.96) EP (34) Countries for which the regional or international application was filed: DE et al.</p> <p>(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B- 2340 Beerse (BE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): JANSSENS, Frans, Ed- uard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE) LEENAERTS, Joseph, Elisabeth [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE) SOMMEN, François, Maria [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE) SURLERAUX, Dominique, Louis, Nestor,</p>	<p>Ghislaine [BE/BE]; Janssen Pharmaceutica N.V., Turnhout- seweg 30, B-2340 Beerse (BE).</p> <p>(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>	

(54) Title: FUSED IMIDAZOLE DERIVATIVES AS MULTIDRUG RESISTANCE MODULATORS

(57) Abstract

This invention concerns the compounds of formula (I), the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein the dotted line is an optional bond, *n* is 1 or 2; *R*¹ is hydrogen; halo; formyl; C₁-alkyl optionally substituted with hydroxy, C₁-alkyloxy, C₁-alkylcarbonyloxy, imidazolyl, thiazolyl or oxazolyl; or a radical of formula -X-COOR⁶, -X-CONR⁶R⁷ or -X-COR¹⁰ wherein -X- is a direct bond, C₁-alkanediyl or C₂-alkenediyl; *R*⁵ is hydrogen, C₁-alkyl, Ar, Het, C₁-alkyl substituted with C₁-alkyloxy, aryl or heteroaryl; *R*⁶ and *R*⁷ each independently are hydrogen or C₁-alkyl; *R*² is hydrogen, halo, C₁-alkyl, hydroxyC₁-alkyl, C₁-alkyloxycarbonyl, carboxyl, formyl or phenyl; *R*³ is hydrogen, C₁-alkyl or C₁-alkyloxy; *R*⁴ is hydrogen, halo, C₁-alkyl, C₁-alkyloxy or haloC₁-alkyl; *Z* is -CH₂-, -CH₂-CH₂-, -CH=CH-, -CHOH-CH₂-, -O-CH₂-, -C(=O)-CH₂- or -C(=NOH)-CH₂-; -A-B- is a bivalent radical; *A*¹ is a direct bond, optionally substituted C₁-alkanediyl, C₁-alkanediyl-oxy-C₁-alkanediyl, carbonyl, C₁-alkanediylcarbonyl, optionally substituted C₁-alkanediyoxy; *A*² is a direct bond or C₁-alkanediyl; and *Q* is aryl. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for inhibiting or reversing the effects of multidrug resistance.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

FUSED IMIDAZOLE DERIVATIVES AS
MULTIDRUG RESISTANCE MODULATORS

5 This invention relates to fused imidazole derivatives having multidrug resistance modulating properties, and processes for their preparation; it further relates to compositions comprising them, as well as their use as a medicine.

10 Chemotherapy is one of the most frequently used forms of cancer therapy and has found clinical applications in the treatment of almost every type of cancer. One of the major problems in cancer chemotherapy is the development of resistance to cytotoxic drugs. Patients who did respond to a first course of chemotherapy frequently relapse because tumor cells seem to develop resistance against chemotherapeutic agents or may acquire resistance to a cytotoxic agent used in a previous treatment. A tumor may also manifest
15 resistance to a cytotoxic agent to which it has not previously been exposed, that agent being unrelated by structure or mechanism of action to any agent used in previous treatments of the tumor. Examples of these effects can be seen in, for example, haematological tumors (leukemias, lymphomas), renal carcinoma and breast carcinoma.

20 Analogously, certain pathogens may acquire resistance to pharmaceutical agents used in previous treatments of the diseases or disorders to which those pathogens give rise. Pathogens may also manifest resistance to pharmaceutical agents to which they have not previously been exposed. Examples of this effect include multidrug resistance forms of malaria, tuberculosis, leishmaniasis and amoebic dysentery.

25 The above phenomena by which cancer cells or pathogens become resistant to multiple drugs that have little similarity in their structure or mechanism of action, are referred to collectively as multidrug resistance (MDR).

30 As used throughout the text, MDR modulators or compounds having MDR modulating properties are defined as compounds which are able to decrease, avoid, eliminate, inhibit or reverse the effects of multidrug resistance.

35 Since MDR is a major problem for the chemotherapeutic approach of the above-mentioned disorders, compounds capable of inhibiting or reversing the effects of multidrug resistance would be very useful.


EP-0.518.435 and EP-0.518.434, published on December 16 1992, disclose fused

-2-

imidazole compounds having antiallergic activity. WO-94/13680 published June 23, 1994, discloses substituted imidazo[1,2-a](pyrrolo, thieno and furano) [2,3-d]azepine derivatives having antiallergic activity. Also, WO 95/02600, published on January 26, 1995, discloses other piperidiny- or piperidinylidene substituted imidazoazepine derivatives also having antiallergic activity.

The compounds of the present invention differ from the cited art-known compounds structurally, by the nature of the substituents on the nitrogen of the piperidine moiety, and pharmacologically by the fact that, unexpectedly, these compounds have MDR modulating properties.

This invention concerns compounds of formula



the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein

the dotted line is an optional bond;

n is 1 or 2;

R¹ is hydrogen; halo; formyl; C₁₋₄alkyl; C₁₋₄alkyl substituted with 1 or 2 substituents each independently selected from hydroxy, C₁₋₄alkyloxy, C₁₋₄alkylcarbonyloxy, imidazolyl, thiazolyl or oxazolyl; or a radical of formula

-X-CO-OR⁵ (a-1);

-X-CO-NR⁶R⁷ (a-2); or

-X-CO-R¹⁰ (a-3);

wherein -X- is a direct bond, C₁₋₄alkanediyl or C₂₋₆alkenediyl;

R⁵ is hydrogen; C₁₋₁₂alkyl; Ar; Het; C₁₋₆alkyl substituted with C₁₋₄alkyloxy, C₁₋₄alkyloxycarbonyl, C₁₋₄alkyloxy, Ar or Het;

R⁶ and R⁷ each independently are hydrogen or C₁₋₄alkyl;

R¹⁰ is imidazolyl, thiazolyl or oxazolyl;

-3-

- R^2 is hydrogen, halo, C_{1-4} alkyl, hydroxy C_{1-4} alkyl, C_{1-4} alkyloxycarbonyl, carboxyl, formyl or phenyl;
- R^3 is hydrogen, C_{1-4} alkyl or C_{1-4} alkyloxy;
- R^4 is hydrogen, halo, C_{1-4} alkyl, C_{1-4} alkyloxy or halo C_{1-4} alkyl;
- 5 Z is Z^1 or Z^2 ;
- wherein Z^1 is a bivalent radical of formula $-CH_2-$, $-CH_2-CH_2-$ or $-CH=CH-$; provided that when the dotted line is a bond, then Z^1 is other than $-CH_2-$;
- Z^2 is a bivalent radical of formula $-CHOH-CH_2-$, $-O-CH_2-$, $-C(=O)-CH_2-$ or $-C(=NOH)-CH_2-$;
- 10 $-A-B-$ is a bivalent radical of formula
- $-Y-CR^8=CH-$ (b-1);
- $-CH=CR^8-Y-$ (b-2);
- $-CH=CR^8-CH=CH-$ (b-3);
- $-CH=CH-CR^8=CH-$ (b-4); or
- 15 $-CH=CH-CH=CR^8-$ (b-5);
- wherein each R^8 independently is hydrogen, halo, C_{1-4} alkyl, C_{1-4} alkyloxy, hydroxy C_{1-4} alkyl, hydroxycarbonyl C_{1-4} alkyl, formyl, carboxyl, ethenyl substituted with carboxyl, or ethenyl substituted with C_{1-4} alkyloxycarbonyl;
- 20 each Y independently is a bivalent radical of formula $-O-$, $-S-$ or $-NR^9-$;
- wherein R^9 is hydrogen, C_{1-4} alkyl or C_{1-4} alkylcarbonyl;
- $-A^1-$ is a direct bond; C_{1-6} alkanediyl; C_{1-6} alkanediyl-oxy- C_{1-6} alkanediyl; C_{1-6} alkanediyoxy; carbonyl; C_{1-6} alkanediylcarbonyl; C_{1-6} alkanediyoxy substituted with hydroxy; or C_{1-6} alkanediyl substituted with hydroxy or $=NOH$;
- 25 $-A^2-$ is a direct bond or C_{1-6} alkanediyl;
- Q is phenyl; phenyl substituted with one or two substituents selected from hydrogen, halo, hydroxy, C_{1-4} alkyl, C_{1-4} alkyloxy or halo C_{1-4} alkyl; naphthalenyl; naphthalenyl substituted with one or two substituents selected from hydrogen, halo, hydroxy, C_{1-4} alkyl, C_{1-4} alkyloxy or halo C_{1-4} alkyl; pyridinyl; pyridinyl substituted with one
- 30 or two substituents selected from hydrogen, halo, hydroxy, C_{1-4} alkyl, C_{1-4} alkyloxy or halo C_{1-4} alkyl; quinolinyl; or quinolinyl substituted with one or two substituents selected from hydrogen, halo, hydroxy, C_{1-4} alkyl, C_{1-4} alkyloxy or halo C_{1-4} alkyl;
- Ar is phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from hydrogen, halo, C_{1-4} alkyl or C_{1-4} alkyloxy;
- 35 Het is furanyl; furanyl substituted with C_{1-4} alkyl, C_{1-4} alkyloxy or hydroxy C_{1-4} alkyl; oxazolyl; oxazolyl substituted with C_{1-4} alkyl or C_{1-4} alkyloxy; or quinolinyl.

As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; C₁₋₄alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, 1-methylethyl, 2-methylpropyl, 2,2-dimethylethyl and the like; C₁₋₆alkyl includes C₁₋₄alkyl and the higher homologues thereof having from 5 to 6 carbon atoms such as, for example, pentyl, hexyl, 3-methylbutyl, 2-methylpentyl and the like; C₁₋₁₂alkyl includes C₁₋₆alkyl and the higher homologues thereof having from 7 to 12 carbon atoms such as, for example, heptyl, octyl, nonyl, decyl and the like; C₁₋₄alkanediyl defines bivalent straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl and the like; C₁₋₅alkanediyl includes C₁₋₄alkanediyl and the higher homologues thereof having 5 carbon atoms such as, for example, 1,5-pentanediyl and the like; C₁₋₆alkanediyl includes C₁₋₅alkanediyl and the higher homologues thereof having 6 carbon atoms such as, for example, 1,6-hexanediyl and the like; C₂₋₆alkenyl defines straight and branched chain hydrocarbon radicals containing one double bond and having from 2 to 6 carbon atoms such as, for example, ethenyl, 2-propenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, and the like; C₂₋₆alkenediyl defines straight and branched chain hydrocarbon radicals containing one double bond and having from 2 to 6 carbon atoms such as, for example, ethenediyl, 2-propenediyl, 3-butenediyl, 2-pentenediyl, 3-pentenediyl, 3-methyl-2-butenediyl, and the like; haloC₁₋₄alkyl is defined as mono- or polyhalosubstituted C₁₋₄alkyl; C₁₋₆alkanediyl-oxy-C₁₋₆alkanediyl defines bivalent radicals of formula such as, for example, -CH₂-CH₂-O-CH₂-CH₂-, -CH₂-CH(CH₂CH₃)-O-CH(CH₃)-CH₂-, -CH(CH₃)-O-CH₂- and the like.

Whenever the bivalent radical A¹ is defined as a C₁₋₆alkanediylcarbonyl or C₁₋₆alkanediylloxy, preferably the C₁₋₆alkanediyl part of said radicals is connected to the nitrogen atom of the piperidine ring.

Pyridinyl and quinolinyl in the definition of Q are preferably connected to A² by a carbon atom.

Whenever Z is defined as Z², the -CH₂- moiety of said bivalent radical is preferably connected to the nitrogen of the imidazole ring.

Wherever R¹ or R¹⁰ is defined as imidazolyl, thiazolyl or oxazolyl, said substituents are preferably connected by a carbon atom to the rest of the molecule.

5 The compounds where Z is -CH₂- and the optional bond is present are excluded by proviso because the tricyclic moiety in such compounds spontaneously aromatizes, thereby losing its multidrug resistance modulating properties.

10 The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The latter can conveniently be obtained by treating the base form with such appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic
15 (i.e. butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-aminosalicylic, pamoic and the like acids.

20 The pharmaceutically acceptable addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic base addition salt forms which the compounds of formula (I) are able to form. Examples of such base addition salt forms are, for example, the sodium, potassium, calcium salts, and also the salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, *N*-methyl-D-glucamine, hydrabamine, amino acids, e.g. arginine, lysine.
25

Conversely said salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form.

30 The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) as well as the salts thereof, are able to form. Such solvates are for example hydrates, alcoholates and the like.

35 The term stereochemically isomeric forms as used hereinbefore defines the possible different isomeric as well as conformational forms which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically and conformationally isomeric forms, said mixtures containing all diastereomers, enantiomers and/or

conformers of the basic molecular structure. All stereochemically isomeric forms of the compounds of formula (I) both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.

- 5 Some compounds of the present invention may exist in different tautomeric forms and all such tautomeric forms are intended to be included within the scope of the present invention. For instance, compounds of formula (I) wherein Q is pyridinyl or quinolinyl substituted with hydroxy, may exist in their corresponding tautomeric form.
- 10 The *N*-oxide forms of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the so-called *N*-oxide, particularly those *N*-oxides wherein the piperidine-nitrogen is *N*-oxidized.
- 15 A first group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply :
 - a) -A-B- is a bivalent radical of formula (b-2), (b-3) or (b-4); or
 - b) Z is Z¹ wherein Z¹ is a bivalent radical of formula -CH₂-CH₂- or -CH₂-; or
 - c) -A¹- is C₁₋₆alkanediyl, C₁₋₆alkanediyloxy, carbonyl, C₁₋₆alkanediyloxy substituted
 - 20 with hydroxy, or C₁₋₆alkanediyl substituted with hydroxy; in particular -A¹- is C₁₋₆alkanediyl; or
 - d) -A²- is a direct bond or C₁₋₆alkanediyl; in particular -A²- is C₁₋₆alkanediyl;
 - e) Q is phenyl, naphthalenyl, pyridinyl or quinolinyl, and optionally said Q is substituted with halo, C₁₋₆alkyl or C₁₋₆alkyloxy;
 - 25 f) R¹ is hydrogen, halo, formyl, C₁₋₄alkyl substituted with hydroxy, or a radical of formula (a-1) wherein X is a direct bond or C₁₋₄alkanediyl and R⁵ is hydrogen, C₁₋₁₂alkyl, Ar or C₁₋₆alkyl substituted with Het;
 - g) R² is hydrogen, halo, C₁₋₄alkyl, formyl, hydroxyC₁₋₄alkyl or C₁₋₄alkyloxycarbonyl;
 - h) R³ is hydrogen;
 - 30 i) R⁴ is hydrogen, halo, C₁₋₆alkyl or C₁₋₆alkyloxy.

A second group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply :

- a) -A-B- is a bivalent radical of formula (b-2), (b-3) or (b-4); or
- 35 b) Z is Z² wherein Z² is a bivalent radical of formula -C(=O)-CH₂-; or

-7-

- c) -A¹- is C₁₋₆alkanediyl, C₁₋₆alkanediyloxy, carbonyl, C₁₋₆alkanediyloxy substituted with hydroxy, or C₁₋₆alkanediyl substituted with hydroxy; in particular -A¹- is C₁₋₆alkanediyl; or
- d) -A²- is a direct bond or C₁₋₆alkanediyl; in particular -A²- is C₁₋₆alkanediyl;
- 5 e) Q is phenyl, naphthalenyl, pyridinyl or quinolinyl, and optionally said Q is substituted with halo, C₁₋₆alkyl or C₁₋₆alkyloxy;
- f) R¹ is hydrogen, halo, formyl, C₁₋₄alkyl substituted with hydroxy, or a radical of formula (a-1) wherein X is a direct bond or C₁₋₄alkanediyl and R⁵ is hydrogen, C₁₋₁₂alkyl, Ar or C₁₋₆alkyl substituted with Het;
- 10 g) R² is hydrogen, halo, C₁₋₄alkyl, formyl, hydroxyC₁₋₄alkyl or C₁₋₄alkyloxycarbonyl;
- h) R³ is hydrogen;
- i) R⁴ is hydrogen, halo, C₁₋₆alkyl or C₁₋₆alkyloxy.

15 A particular group of compounds are those compounds of formula (I) wherein -A-B- is a bivalent radical of formula (b-2), (b-3) or (b-4) wherein R⁸ is hydrogen or halo; Z is -CH₂-CH₂-; -A¹- is -CH₂-CH₂-, -CH₂-CH₂-CH₂- or -O-CH₂-CH₂-; A²- is -CH₂- and the dotted line is a bond.

20 Another particular group of compounds are those compounds of formula (I) wherein Q is 2-quinolinyl, 1-naphthalenyl, 2-naphthalenyl, phenyl or 2-pyridinyl and said Q is optionally substituted with C₁₋₄alkyl, halo, haloC₁₋₄alkyl or C₁₋₄alkyloxy.

25 A further particular group are those compounds of formula (I) wherein Q is 2-quinolinyl, 1-naphthalenyl, 2-naphthalenyl, 6-methyl-2-quinolinyl, 6-chloro-2-pyridinyl, 4-methoxyphenyl, 3,5-dimethylphenyl, 3,5-difluorophenyl, or 3,5-bis(trifluoromethyl)phenyl.


30 Preferred compounds are those compounds of formula (I) wherein Z is -CH₂-CH₂-; -A-B- is -CH=CH-CH=CH-; -A¹- is -CH₂-CH₂- or -O-CH₂-CH₂-; -A²- is -CH₂-; R¹ is hydrogen, halo, formyl or a radical of formula (a-1) wherein X is a direct bond and R⁵ is hydrogen, C₁₋₁₂alkyl, Ar or C₁₋₆alkyl substituted with Het; R² is hydrogen, C₁₋₄alkyl, formyl or C₁₋₄alkyloxycarbonyl; R³ is hydrogen; R⁴ is hydrogen or C₁₋₄alkyloxy and the dotted line is a bond.

35 Most preferred compounds of formula (I) are methyl 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate;


-8-

- dimethyl 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidin-ylidene]-5*H*-imidazo[2,1-b][3]benzazepine-2,3-dicarboxylate;
- ethyl 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[2,1-b][3]benzazepine-3-carboxylate;
- 5 methyl 11-[1-[3,5-dimethoxy-4-(2-quinolinylmethoxy)phenyl]methyl]-4-piperidinylidene]-6,11-dihydro-5*H*-imidazo[2,1-b][3]benzazepine-3-carboxylate;
- methyl 6,11-dihydro-11-[1-[3-[4-(2-quinolinylmethoxy)phenyl]propyl]-4-piperidinylidene]-5*H*-imidazo[2,1-b][3]benzazepine-3-carboxylate;
- methyl 6,11-dihydro-11-[1-[2-[4-(2-naphthalenylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[2,1-b][3]benzazepine-3-carboxylate;
- 10 methyl 6,11-dihydro-11-[1-[2-[4-(phenylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[2,1-b][3]benzazepine-3-carboxylate; and
- methyl 6,11-dihydro-11-[1-[2-[4-(1-naphthalenylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[2,1-b][3]benzazepine-3-carboxylate; the stereoisomeric forms and
- 15 the pharmaceutically acceptable addition salts thereof.


- In the following paragraphs there are described different ways of preparing the compounds of formula (I). In order to simplify the structural formulae of the compounds of formula (I) and the intermediates intervening in their preparation, the
- 20 fused imidazole moiety will be represented by the symbol T hereinafter.




- The compounds of the present invention can generally be prepared by *N*-alkylating an intermediate of formula (III) wherein W is an appropriate leaving group such as, for example, chloro, bromo, methanesulfonyloxy or benzenesulfonyloxy, with an intermediate of formula (II). The reaction can be performed in a reaction-inert solvent such as, for example, ethanol, dichloromethane, methyl isobutylketone or *N,N*-dimethylformamide, and in the presence of a suitable base such as, for example,
- 25 sodium carbonate, sodium hydrogen carbonate or triethylamine. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried out at a temperature ranging between room temperature and reflux temperature.
- 30



Compounds of formula (I) may also be prepared by *O*-alkylating an intermediate of formula (V) with an intermediate of formula (IV), wherein W¹ is an appropriate leaving group such as, for example, chloro, bromo, methanesulfonyloxy or benzenesulfonyloxy. The reaction can be performed in a reaction-inert solvent such as, for example, *N,N*-dimethylformamide, and in the presence of a suitable base such as, for example, sodium hydride, preferably at a temperature ranging between room temperature and reflux temperature.




Compounds of formula (I) wherein -A¹- represents C₁₋₆alkanediyl, C₁₋₆alkanediyl-oxy, C₁₋₆alkanediyl-oxyC₁₋₆alkanediyl, said compounds being represented by formula (I-i), may be prepared by reductive *N*-alkylation of an intermediate of formula (III) with an intermediate of formula (XIX). In said intermediate (XIX), -A¹- represents a direct bond, C₁₋₅alkanediyl, C₁₋₅alkanediyl-oxy or a C₁₋₆alkanediyl-oxyC₁₋₅alkanediyl moiety whereby the formyl group is bonded on the C₁₋₅alkanediyl part.




Said reductive *N*-alkylation may be performed in a reaction-inert solvent such as, for example, dichloromethane, ethanol, toluene or a mixture thereof, and in the presence of a reducing agent such as, e.g. sodium borohydride, sodium cyanoborohydride or triacetoxy borohydride. It may also be convenient to use hydrogen as a reducing agent

in combination with a suitable catalyst such as, for example, palladium-on-charcoal or platinum-on-charcoal. In case hydrogen is used as reducing agent, it may be advantageous to add a dehydrating agent to the reaction mixture such as, for example, aluminium *tert*-butoxide. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may also be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g., thiophene or quinoline-sulphur. To enhance the rate of the reaction, the temperature may be elevated in a range between room temperature and the reflux temperature of the reaction mixture.

In the following paragraphs there are described different ways of converting compounds of formula (I) into each other following art-known functional group transformation procedures. In order to simplify the structural formulae of the compounds of formula (I), the substituted piperidine moiety will be represented by the symbol M hereinafter.




For instance, compounds of formula (I) wherein R^1 is C_{1-4} alkyl substituted with hydroxy, said compounds being represented by formula (I-a), may be converted in the corresponding compounds of formula (I) wherein R^1 is C_{1-4} alkylcarbonyloxy C_{1-4} alkyl, said compounds being represented by formula (I-b), according to art-known esterification methods such as, e.g. treatment with an acyl halide in the presence of a base to pick up the acid liberated during the reaction.



Also, compounds of formula (I-a) wherein R^1 is CH_2OH , said compounds being represented by formula (I-a-1), may be converted in the corresponding compounds of

-11-


formula (I) wherein R^1 is CHO, said compounds being represented by formula (I-c), by oxidation with a suitable reagent such as, e.g. manganese(IV)oxide.



5

Further, compounds of formula (I) wherein R^1 contains a carboxyl group, said compounds being represented by formula (I-d), may be converted in the corresponding esters by art-known methods such as, e.g. treatment with an alcohol in the presence of an acid or base.

10




Conversely, compounds of formula (I-e) may be hydrolyzed into compounds of formula (I-d), in the presence of an acid or a base.

15


The compounds of formula (I-c) may be converted into compounds of formula (I) wherein R^1 is a methoxycarbonylmethyl, said compounds being represented by formula (I-f), by treatment with methyl methylthiomethyl sulfoxide in the presence of benzyltrimethyl ammonium hydroxide in a reaction-inert solvent, e.g. tetrahydrofuran.

20




Also, compounds of formula (I-c) may be converted into compounds of formula (I-e) wherein X is a direct bond, said compounds being represented by formula (I-e-1), by treatment with an alcohol, such as, e.g. methanol or ethanol, in the presence of acetic acid, MnO₂ and NaCN.

5



Compounds of formula (I) wherein Z² represents -C(=O)-CH₂-, said compounds being represented by formula (I-g), can be converted in the corresponding alcohols by art-known reduction procedures such as, e.g. treatment with sodiumborohydride in a suitable solvent, e.g. methanol.

10




The starting materials and some of the intermediates are known compounds and are commercially available or may be prepared according to conventional reaction procedures generally known in the art. For example, a number of intermediates of formula (III), especially those wherein Z is Z², are known compounds which may be prepared according to art-known methodologies described in EP-0,518,435-A, EP-0,518,434-A and WO-95/02600.

20


In the following paragraphs there are described several methods of preparing the intermediates employed in the foregoing preparations.

- The intermediates of formula (II) may be prepared by *O*-alkylating the aromatic hydroxyl group of intermediate (VI) with an intermediate of formula (IV), wherein W¹ is a suitable leaving group such as, e.g. halo, methanesulfonyloxy or benzenesulfonyloxy, and subsequent conversion of the hydroxy group of intermediate (VII) into leaving group W, e.g. by treating intermediate (VII) with methanesulfonyloxy chloride or a halogenating reagent such as, e.g. POCl₃.




- 10 Said *O*-alkylation reaction can conveniently be carried out by mixing the reactants in a reaction-inert solvent such as, for example, methanol or *N,N*-dimethylformamide, and in the presence of an appropriate base such as, e.g. sodium carbonate or sodium hydrogen carbonate, preferably at a temperature ranging between room temperature and the reflux temperature of the reaction mixture.

- 15 Also, intermediates of formula (II) wherein -A¹- is C₁₋₆alkanediyl, said intermediates being represented by compounds of formula (II-a), may be prepared by reacting an intermediate of formula (VIII) with an intermediate of formula (IX) in the presence of an appropriate base such as, e.g. potassium carbonate, and optionally in the presence of a reaction-inert solvent such as, for example, *N,N*-dimethylformamide, acetonitrile or tetrahydrofuran. Subsequent conversion of the hydroxy group into a leaving group W, e.g. by treatment with methanesulfonyloxy chloride or a halogenating reagent such as, e.g. POCl₃, yields intermediates of formula (II-a). It may be advantageous to conduct said *O*-alkylation reaction at a temperature ranging between room temperature and reflux temperature.




In an embodiment, the present invention also provides for novel compounds of formula (II), represented by compounds of formula (II-b) wherein radical -A^{1'}- represents C₁₋₆alkanediyl, C₁₋₆alkanediyoxy or C₁₋₆alkanediyoxyC₁₋₆alkanediyl and Q¹ represents all substituents Q other than unsubstituted phenyl.

5




Intermediates of formula (V) wherein -A^{1'}- represents C₁₋₆alkanediyl, C₁₋₆alkanediyoxy, C₁₋₆alkanediyoxyC₁₋₆alkanediyl, said intermediates being represented by formula (V-a), may be prepared by reductive *N*-alkylation of an intermediate of formula (III) with an intermediate of formula (X). Optionally, intermediate (X) has a protected hydroxyl group which can be deprotected using art-known methods subsequent to the reductive *N*-alkylation. In said intermediate (X), -A^{1''}- represents a direct bond, C₁₋₅alkanediyl, C₁₋₅alkanediyoxy or C₁₋₆alkanediyl-oxyC₁₋₅alkanediyl whereby the formyl group is bonded on the C₁₋₅alkanediyl part. Said reductive *N*-alkylation may be performed according to the hereinabove described procedure.

20




Intermediates of formula (III-a), defined as intermediates of formula (III) wherein Z is Z¹, may be prepared according to scheme I.

Scheme I




-15-




- In scheme I, an intermediate of formula (XII) can be cyclized in an analogous way as an intermediate of formula (XI), giving an alcohol of formula (XIII) which can be oxidized following art-known oxidation methods into a ketone of formula (XIV). An intermediate of formula (XVI) can be prepared by addition of a Grignard reagent (XV), wherein PG is a suitable protecting group, e.g. benzyl, to a ketone of formula (XIV) in a reaction-inert solvent, e.g. tetrahydrofuran. An intermediate of formula (III-a) can be prepared by dehydration of an intermediate (XVI) subsequently with catalytic hydrogenation of an intermediate (XVII). Said dehydration reaction can conveniently be conducted employing conventional dehydrating reagents, e.g. sulfuric acid, following art-known methodologies. Said catalytic hydrogenation reaction can be conducted following art-known procedures, e.g. stirring in a reaction-inert solvent, e.g. methanol, in the presence of a suitable catalyst, e.g. palladium-on-carbon and in the presence of hydrogen, optionally the temperature may be elevated in a range between room temperature and the reflux temperature of the reaction mixture and, if desired, the pressure of the hydrogen gas may be raised.
- Further, intermediates of formula (III-a) wherein R^1 is halo, said intermediates being represented by formula (III-a-1), can be prepared by halogenating intermediates of formula (XVIII), wherein PG is a protective group such as, e.g. C_{1-6} alkyl, and subsequent deprotection. For instance, when PG is C_{1-6} alkyl, PG may be removed by a carbonylation reaction with a C_{1-4} alkylchloroformate and subsequent hydrolysis with a base.

-16-



Said halogenation reaction can conveniently be conducted by treating intermediates (XVIII) with a halogenating reagent such as, for example, *N*-chlorosuccinimide or *N*-bromosuccinimide, in a reaction-inert solvent such as, e.g. dichloromethane, optionally in the presence of an initiator such as, e.g. dibenzoyl peroxide.

Also, the intermediates of formula (III) wherein Z is Z¹ and the dotted line is not a bond, said intermediates being represented by compounds of formula (III-b), can generally be prepared by cyclizing an intermediate of formula (XI).



Said cyclization reaction is conveniently conducted by treating an intermediate of formula (XI) with an appropriate acid, yielding an intermediate of formula (III-a). Appropriate acids are, for example, methanesulfonic acid or trifluoromethanesulfonic acid. It should be noted that only those intermediates of formula (III-a) wherein R¹ and R² are stable under the given reaction conditions can be prepared according to the above reaction procedure.

Compounds of formula (I) and some of the intermediates may have one or more stereogenic centers in their structure, present in a R or a S configuration.

The compounds of formula (I) as prepared in the hereinabove described processes may be synthesized as a mixture of stereoisomeric forms, in particular in the form of racemic mixtures of enantiomers which can be separated from one another following

art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

The compounds of formula (I), the *N*-oxide forms, the pharmaceutically acceptable addition salts and stereoisomeric forms thereof have valuable pharmacological properties in that they inhibit or reverse the effects of multidrug resistance, as can be evidenced by the results obtained in the MDR *in vitro* test (Example C-1) and the MDR *in vivo* test (Example C-2).

The term multidrug resistance (MDR) describes the phenomenon by which cells, in particular cancer cells, or pathogens become resistant to multiple drugs that may have little similarity in the structure or mechanism of action. The major cause of MDR is overexpression of a membrane-associated transporter, *i.e.* P-glycoprotein, which decreases the intracellular concentration of cytotoxic drugs by binding the drug and actively pumping it out of the cell before it reaches a critical cytotoxic concentration (Dalton W.S., *Seminars in oncology*, 20:66-69, 1993).

Other resistance mechanisms include alterations in topoisomerase, glutathione S-transferase, nucleoside transport, thymidilate synthase, dihydrofolate reductase and metallothionein.

Further, the compounds of formula (I) are useful in inhibiting transport of a chemotherapeutic agent through a membrane by a membrane-associated transporter, especially the membrane-associated transporter P-glycoprotein, and thereby maintaining effectiveness of this agent.

In view of their MDR inhibiting or reversing activity, the compounds of formula (I) are suitable for use as a medicine, in particular for decreasing, eliminating or reversing a

developing or existing resistance to chemotherapeutic drug therapy, or avoiding such resistance from arising, by administration of a therapeutically effective amount of a compound of formula (I). Diseases, disorders or conditions wherein treatment is hampered by multidrug resistance are, for example, neoplastic diseases caused by the growth of neoplasms (or tumors) such as, for example, haematological tumors (leukemias, lymphomas), renal carcinoma, ovarian, breast carcinoma, melanoma, tumors in the colon and lungs and the like, and diseases such as, e.g. multidrug resistance forms of malaria, tuberculosis, leishmaniasis, amoebic dysentery and the like, caused by pathogens which acquired resistance to pharmaceutical agents such as, e.g. chloroquine, pyrimethamine-sulfadoxime, mefloquine, halofantrine, isoniazid, streptomycin, rifampicin, pyrazinamide, nalidixic acid, ampicillin and the like.

The compounds of formula (I) may conveniently be used in combination with a chemotherapeutic agent. The invention thus provides a combination comprising a composition as defined herein, together with a therapeutically active agent, in particular an anti-neoplastic agent. The combination may be administered separately, simultaneously, concurrently or consecutively by any of the routes described above, or the combination may also be presented in the form of one pharmaceutical formulation. Thus, a pharmaceutical product comprising (a) a compound of formula (I) and (b) a chemotherapeutic agent as defined hereinbefore, as a combined preparation for simultaneous, separate or sequential use in the therapeutic or prophylactic treatment of warm-blooded animals suffering from disorders or conditions wherein multidrug resistance hampers the treatment. Such a product may comprise a kit comprising a container containing a pharmaceutical composition of a compound of formula (I), and another container comprising a pharmaceutical composition of the chemotherapeutic agent. The product with separate compositions of the two active ingredients has the advantage that appropriate amounts of each component, and timing and sequence of administration can be selected in function of the patient.

Suitable chemotherapeutic agents for use in the combinations defined above include are, for example, anti-neoplastic agents such as, e.g. adriamycine, daunorubicin, doxorubicin, vincristine, vinblastine, etoposide, taxol, taxotere, dactinomycin, mitoxantrone, mitomycin, trimetrexate and the like, for the treatment of neoplastic diseases and pharmaceutical agents such as, e.g. chloroquine, pyrimethamine-sulfadoxime, mefloquine, halofantrine, isoniazid, streptomycin, nalidixic acid and

ampicillin, for the treatment of diseases caused by pathogens which acquired resistance to multiple pharmaceutical agents.

5 When compounds of formula (I) are used in combination with a chemotherapeutic agent, the dose of the chemotherapeutic agent may vary from the dose when used alone. Thus when compounds of formula (I) are used together with a chemotherapeutic agent the dose of the latter may be the same or more commonly, lower, than the dose employed when the chemotherapeutic agent is used alone. Appropriate doses will be readily appreciated by those skilled in the art.

10

In view of the above uses of the compounds of formula (I), it follows that the present invention also provides a method of treating warm-blooded animals suffering from those diseases or conditions wherein treatment is hampered by multidrug resistance, said method comprising the systemic administration of a therapeutic amount of a
15 compound of formula (I) effective in avoiding, inhibiting or reversing the effects of multidrug resistance.

The present invention provides a method for the use of compounds of formula (I) for decreasing, eliminating or reversing a developing or existing resistance to anti-
20 neoplastic drug therapy, or avoiding such resistance from arising, by administration of a therapeutically effective amount of a compound of formula (I).

Also, a method is provided for the use of compounds of formula (I) in the treatment of diseases or conditions caused by pathogens which have acquired resistance to
25 pharmaceutical agents, said method comprising the systemic administration of a therapeutic amount of a compound of formula (I) effective in inhibiting or reversing multidrug resistance, and a pharmaceutical agent useful to treat those conditions.

For ease of administration, the subject compounds may be formulated into various
30 pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These
35 pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be

employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.

Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid addition salts of (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

The compositions may advantageously be presented in discrete dose units, especially in unit dosage forms. A convenient unit dose formulation contains the active ingredient in an amount of from 0.1 to 1000 mg, and in particular from 1 to 200 mg. The amount of a compound of formula (I) required as daily dose in treatment will vary not only with the particular compound selected, but also with the route of administration, the nature of the condition being treated and the age, weight and condition of the patient and will

ultimately be at the discretion of the attendant physician. In general, however, a suitable daily dose will be in the range of from about 0.1 to about 5000 mg per day, in particular from about 1 to 1000 mg per day, more particular from about 10 to 500 mg per day. A suitable daily dose for use in prophylaxis will generally be in the same range.

The following examples are provided for purposes of illustration, not limitation.

Experimental part

10 A. Preparation of the intermediates.

Hereinafter "THF" means tetrahydrofuran, "DIPE" means diisopropylether, "DCM" means dichloromethane, "DMF" means *N,N*-dimethylformamide and "ACN" means acetonitrile.

15 Example A.1

- a) 4-Hydroxybenzeneethanol (103.5 g) was stirred in ethanol (1.5 l), at room temperature. A solution of potassium hydroxide (84 g) in ethanol (1.5 l) was added dropwise, over a 1 hour period. 2-(Chloromethyl)quinoline monohydrochloride was added portionwise over a 25-minutes period. The reaction mixture was stirred and refluxed for 12 hours. The reaction mixture was poured out into water (5 l) and this mixture was stirred vigorously. The precipitate was filtered off, and washed with water (2 l). Toluene was added and azeotroped on the rotary evaporator. The residue was dried, yielding 187 g (89%) of 4-(2-quinolinylmethoxy)benzeneethanol (intermediate 1, mp. 144.8°C).
- 25 b) A mixture of intermediate 1 (2.79 g) and *N,N*-diethylethanamine (1.2 g) in DCM (50 ml) was stirred on an ice bath. Methanesulfonyl chloride (1.26 g) was added dropwise at a temperature below 10°C. The mixture was brought to room temperature and then stirred for 1 hour. Water was added and the mixture was extracted with DCM. The organic layer was washed with water, dried, filtered and evaporated, yielding 3.8 g
- 30 (100%) of 4-(2-quinolinylmethoxy)benzeneethanol methanesulfonate(ester)(interm. 2). In a similar way, 3-(2-quinolinylmethoxy)benzeneethanol methanesulfonate(ester) (intermediate 3) and 4-[(6-methyl-2-quinolinyl)methoxy]benzeneethanol methanesulfonate(ester) (intermediate 4) were synthesized.

35 Example A.2

- a) 3-(2-Quinolinyl-methoxy)phenol (12.5 g), potassium carbonate (10.4 g) and 1,3-dioxolan-2-one (44 g) were stirred on an oil bath at 100°C for 2 hours. The mixture

-22-

- was cooled, poured into water and extracted with DCM. The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 97/3). The pure fractions were collected and evaporated. The residue was stirred up in DIPE. The precipitate was filtered off and dried, yielding 11.9 g (80.6%) of 2-[3-(2-quinolinyl-methoxy)phenoxy]ethanol (intermediate 5).
- b) A mixture of intermediate 5 (2.95 g) and *N,N*-diethylethanamine (1.2 g) in DCM (50 ml) was stirred on an ice bath. Methanesulfonyl chloride (1.26 g) was added dropwise at a temperature below 5°C. The mixture was brought to room temperature and then stirred for 1 hour. Water was added and the mixture was stirred. The mixture was separated and the aqueous layer was extracted with DCM. The combined organic layers were washed with water, dried, filtered and evaporated, yielding 4.5 g (100%) of 2-[3-(2-quinolinyl-methoxy)phenoxy]ethanol methanesulfonate(ester) (intermediate 6). In a similar way, 2-[4-(2-quinolinylmethoxy)phenoxy]ethanol methanesulfonate(ester) (intermediate 7) was synthesized.

Example A.3

- A mixture of 3,5-dimethoxy-4-hydroxybenzaldehyde (8 g) and 6,11-dihydro-11-(4-piperidinylidene)-5*H*-imidazo[2,1-*b*][3]benzazepine (9 g) in methanol (250 ml) and thiophene (4%, 3 ml) was hydrogenated at room temperature with palladium on activated carbon (10%, 2 g) as a catalyst. After uptake of hydrogen (1 equivalent), the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and evaporated, yielding 9.5g (65%) of 4-[4-(5,6-dihydro-11*H*-imidazo[2,1-*b*][3]benzazepin-11-ylidene)-1-piperidinyl]-2,6-dimethoxyphenol (intermediate 8).
- In a similar way, 6,11-dihydro-11-[1-[(4-hydroxy-3,5-dimethoxyphenyl)methyl]-4-piperidinylidene]-5*H*-imidazo[2,1-*b*][3]benzazepine-3-methanol (intermediate 9) was synthesized.

Example A.4

- A mixture of α-[1-(phenylmethyl)-1*H*-imidazol-2-yl]-4-piperidinemethanol (5.4 g) in trifluoromethanesulfonic acid (25 ml) was stirred overnight at 100°C. The reaction mixture was cooled, poured out onto ice, then alkalized with NaOH and this mixture was extracted with DCM. The separated organic layer was dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent

: $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 95/5, upgrading to 90/10). The pure fractions were collected and the solvent was evaporated, yielding 2.5 g (50%) of 5,10-dihydro-10-(4-piperidiny1)-imidazo[1,2-b]isoquinoline (intermediate 10).

5 Example A.5

a) 6,11-Dihydro-11-(1-methyl-4-piperidiny1idene)-5*H*-imidazo[2,1-b][3]benzazepine (28 g) was stirred in DCM (500 ml), until complete dissolution. Dibenzoyl peroxide (0.1 g) was added. *N*-chlorosuccinimide (13.4 g) was added portionwise and the resulting reaction mixture was stirred overnight at room temperature, then for 2 hours at
10 reflux temperature. The solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/(\text{CH}_3\text{OH}/\text{NH}_3)$ 97/3, upgrading to 95/5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from ACN. The precipitate was filtered off and dried, yielding 23.3 g (74%) of 3-chloro-6,11-dihydro-11-(1-methyl-4-piperidiny1idene)-5*H*-imidazo-
15 [2,1-b][3]benzazepine (intermediate 11).

b) A mixture of intermediate 11 (31.4 g) and *N,N*-diethylethanamine (20.2 g) in toluene (1 l) was stirred and refluxed. Ethyl chloroformate (65.1 g) was added dropwise. The reaction mixture was stirred and refluxed for 90 minutes. The mixture was cooled. Water and K_2CO_3 were added and the layers were separated. The aqueous layer was
20 extracted with toluene. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried, yielding 32.4 g (87%) of ethyl 4-(3-chloro-5,6-dihydro-11*H*-imidazo[2,1-b][3]benzazepin-11-ylidene)-1-piperidinecarboxylate (intermediate 12).

c) A mixture of intermediate 12 (30.4 g) and potassium hydroxide (46 g) in isopropanol (370 ml) was stirred and refluxed for 6 hours. The solvent was evaporated. The residue was taken up in water and extracted with DCM. The organic layer was separated, dried (MgSO_4), filtered and the solvent was evaporated. The residue was crystallized from ACN. The precipitate was filtered off and dried, yielding 1.65 g (90%) of 3-chloro-
25 6,11-dihydro-11-(4-piperidiny1idene)-5*H*-imidazo[2,1-b][3]benzazepine (intermediate 13).
30

B. Preparation of the final products.

Example B.1

A mixture of intermediate 2 (8.6 g), intermediate 13 (6 g) and sodium hydrogen
35 carbonate (2.2 g) in ethanol (300ml) was stirred and refluxed for 48 hours. The solvent was evaporated and the residue was taken up in water and DCM. The layers were

separated and the aqueous layer was extracted with DCM. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was purified on a glass filter over silica gel (eluent : CH₂Cl₂/(CH₃OH/NH₃) 95/5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from ethanol. The precipitate was filtered off and dried, yielding 8.21g (73%) of 3-chloro-6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[2,1-*b*][3]benzazepine (compound 13). In a similar way, 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[2,1-*b*][3]benzazepine-3-methanol (compound 2) was synthesized.

Example B.2

2-(Chloromethyl)quinoline monohydrochloride (4.06 g) was taken up in water, alkalinized with K₂CO₃ and extracted with DCM. The organic layer was dried (MgSO₄), filtered and evaporated, yielding 2-(chloromethyl)quinoline. Sodium hydride (0.7 g) was added at room temperature to a solution of intermediate 8 (6.5 g) in DMF (350 ml) and the mixture was stirred for 30 minutes. 2-(Chloromethyl)quinoline dissolved in DMF was added and the mixture was stirred at 50°C for 3 hours. The mixture was evaporated, the residue was taken up in water and extracted with DCM. The organic layer was dried (MgSO₄), filtered and evaporated. The residue was crystallized from ACN, the precipitate was filtered off, yielding 5.52g (64%) of 11-[1-[[3,5-dimethoxy-4-(2-quinolinylmethoxy)-phenyl]methyl]-4-piperidinylidene]-6,11-dihydro-5*H*-imidazo[2,1-*b*][3]benzazepine (compound 32, mp. 214.8°C).

Example B.3

A mixture of compound 2 (5.56 g) and *N,N*-diethylethanamine (1.2 g) in DCM (100 ml) was stirred at room temperature till complete dissolution. A solution of acetyl chloride (0.86 g) in DCM was added dropwise. The mixture was stirred at room temperature for 1 hour. K₂CO₃ (2 g) and water were added and the mixture was separated into its layers. The aqueous layer was extracted with DCM. The combined organic layer was dried (MgSO₄), filtered and the solvent was evaporated. The residue was crystallized from ACN. The precipitate was filtered off and dried, yielding 3.95g (66%) of [5,6-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-11*H*-imidazo[2,1-*b*][3]benzazepine-3-yl]methanol acetate(ester) (compound 3).

Example B.4

Compound 2 (206 g) was dissolved in DCM (11 l) under continuous stirring. Manganese dioxide (450 g) was added in 100-g portions and the resulting reaction mixture was stirred for 1 hour. The mixture was filtered over dicalite and the filtrate was evaporated. The residue was stirred in ACN, filtered off and dried, yielding 170 g (83%) of 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxaldehyde (compound 4, mp. 193.5°C).

Example B.5

A mixture of compound 4 (8.32 g) and methyl methylthiomethyl sulfoxide (MMTS) (4.5 g) in THF (100 ml) and benzyltrimethyl ammonium hydroxide (40% in methanol; 20 ml) was stirred and refluxed overnight. The solvent was evaporated. The residue was taken up in water and extracted with DCM. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. Toluene was added twice and evaporated again. The residue was taken up in methanol (50 ml). HCl gas was bubbled through the mixture, cooled on an ice bath, for 30 minutes. The mixture was stirred overnight. The solvent was evaporated. The residue was taken up in water, alkalinized with K₂CO₃ and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from ACN. The precipitate was filtered off and dried, yielding 2.7 g (30%) of methyl 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-acetate (compound 5).

Example B.6

A mixture of compound 4 (164 g), sodium cyanate (80 g) and manganese dioxide (500 g) in methanol (5.5 l) was stirred at room temperature. Ethanoic acid (122 g) was added dropwise and the resulting reaction mixture was stirred and refluxed overnight. The reaction mixture was filtered over dicalite, and the filter residue was rinsed with CH₃OH/CH₂Cl₂. The filtrate was evaporated. The residue was partitioned between DCM and aqueous K₂CO₃ solution. The organic layer was separated, dried (MgSO₄), filtered and the solvent was evaporated. The residue was crystallized from ACN. The precipitate was filtered off and dried, yielding 152 g (87%) of methyl 6,11-dihydro-11-

[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[2,1-*b*][3]-benzazepine-3-carboxylate (compound 6, mp. 179.3°C).

Example B.7

- 5 A mixture of compound 6 (37 g) in NaOH (1*N*, 150 ml), THF (500 ml) and water (500 ml) was stirred at room temperature overnight. The organic solvent was evaporated. The aqueous concentrate was washed with DCM and acidified with HCl (1*N*, 150 ml). The solvent was evaporated. The residue was stirred in water, filtered off and dried, yielding 32 g (84%) of 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[2,1-*b*][3]benzazepine-3-carboxylic acid (compound 7, 10 mp. 174.2°C).

Example B.8

- A mixture of compound 27 (3.5 g) in methanol (100 ml) was stirred at room 15 temperature. Sodium borohydride (0.34 g) was added portionwise and the mixture was stirred at room temperature for 2 hours. The mixture was evaporated, the residue was taken up in water and extracted with CH₂Cl₂/C₂H₅OH. The organic layer was dried, filtered and evaporated. The residue was crystallized from ACN. The precipitate was filtered off and dried, yielding 2.39g (68%) of (±)-6,10-dihydro-10-[1-[2-[4-(2-quinolinylmethoxy)-phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[1,2-*a*]thieno[3,2-*d*]azepin-6-ol (compound 28, mp. 242.1°C). 20

Example B.9

- A mixture of compound 7 (3 g) and *N,N*-dimethyl-4-pyridinamine (1.22 g) in DCM 25 (100 ml) was stirred till complete dissolution. 1-(3-Dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (1.8 g) was added portionwise and the mixture was stirred at room temperature for 15 minutes. A solution of benzenemethanol (0.54 g) in DCM was added. The mixture was stirred at room temperature overnight. The solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : 30 CH₂Cl₂/CH₃OH 97/3 to 95/5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from ACN. The precipitate was filtered off and dried, yielding 2.06 g (62%) of phenylmethyl 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[2,1-*b*][3]benzazepine-3-carboxylate (compound 9).
- 35 In a similar way, but replacing the alcohol by ammonia or dimethylamine, compound 55 (compound) and compound 56 (compound) respectively were synthesized.

Example B.10

A mixture of compound 2 (27.8 g) in DCM (500 ml) was stirred at room temperature till complete dissolution. Dibenzoylperoxide (a few crystals) was added portionwise, then a solution of *N*-chlorosuccinimide (7 g) in DCM was added dropwise at room
5 temperature and the mixture was stirred at room temperature for 18 hours. The solvent was evaporated and the residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/(CH₃OH/NH₃) 96/4 to 92/8). The pure fractions were collected and the solvent was evaporated. The residue was purified further by HPLC over silica gel (eluent : CH₂Cl₂/CH₃OH 96/4 to 50/50). The pure fractions were collected and the
10 solvent was evaporated. The first fraction was crystallized from CH₃OH, yielding 8.84g (30%) of compound 59. The second fraction was crystallized from ACN, yielding 1.91 g (6%) of compound 58.

Example B.11

A mixture of compound 6 (5.55 g) and methyl (triphenylphosphoranylidene)acetate (3.34 g) in toluene (300 ml) was stirred and refluxed overnight. The solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from ACN. The precipitate was filtered off,
15 dried, recrystallized from ACN and purified by HPLC Hypersil RP-18 3μM (eluent : (NH₄OAc/0.5% in H₂O)/CH₃OH/CH₃CN 70/15/15, 0/50/50 to 0/0/100). The pure fractions were collected, evaporated till aqueous and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was crystallized from ACN. The precipitate was filtered off and dried, yielding 0.45g (7%)
20 of compound 62.

Example B.12

A mixture of compound 71 (4.5 g) in CH₃OH (350 ml) was stirred on an ice bath. NaBH₄ (0.38 g) was added portionwise at 0°C over a period of 15 minutes. The mixture
30 was stirred at room temperature for 1 hour and then decomposed with water. The organic solvent was evaporated. The aqueous concentrate was extracted with DCM. The combined organic layer was dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. The residue was
35 crystallized from ACN. The precipitate was filtered off and dried, yielding: 3.5g (78%) of compound 73.

Example B.13

A mixture of methyl 6,11-dihydro-4-piperidinylidene-5*H*-imidazo[2,1-*b*][3]benzazepine-3-carboxylate (3.23 g) and *N,N*-dimethyl pyridinamine (2.4 g) in DCM (200 ml) was stirred at room temperature. 1-(3-Dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (3.83 g) was added portionwise. The mixture was stirred at room temperature for 1 hour. 4-(2-Quinolinylmethoxy) benzoic acid (2.8 g) dissolved in DCM was added dropwise. The mixture was stirred at room temperature overnight. Water was added. The mixture was separated into its layers. The aqueous layer was extracted with DCM. The combined organic layer was dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. The residue was dissolved in CH₃OH and converted into the (E)-2-butenedioic acid salt (1:1). The precipitate was filtered off and dried, yielding 3.36 g (48%) of compound 72.

Example B.14

A mixture of compound 71 (4.5 g) and hydroxylamine (1.1 g) in pyridine (50 ml) was stirred and refluxed for 90 minutes. The solvent was evaporated. The residue was stirred in H₂O/CH₂Cl₂. K₂CO₃ (2 g) was added. The mixture was separated into its layers. The aqueous layer was extracted with DCM. The combined organic layer was dried, filtered and the solvent was evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/CH₃OH 95/5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from ACN. The precipitate was filtered off and dried, yielding 1.21 g (26%) of compound 74.


Example B.15

A mixture of 4-phenoxy benzaldehyde (2 g) and methyl 6,11-dihydro-4-piperidinylidene-5*H*-imidazo[2,1-*b*][3]benzazepine-3-carboxylate (3.23 g) in methanol (150 ml) was hydrogenated at room temperature overnight with Pd/C (10%, 1 g) as a catalyst in the presence of a thiophene solution (1 ml). After uptake of hydrogen (1 equivalent), the catalyst was filtered off and the filtrate was evaporated. The residue was purified over silica gel on a glass filter (eluent : CH₂Cl₂/CH₃OH 97/3 to 95/5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from CH₃OH. The precipitate was filtered off and dried, yielding: 2.86 g (57%) of compound 90.

Example B.16

A mixture of diisopropanolamine (1.13 g) in THF was stirred under nitrogen at -78°C. *N*-Butyllithium (2.5 M in hexanes, 4.3 ml) was added portionwise at -70°C and the mixture was stirred for 15 minutes. 1-(Diethoxymethyl)-1*H*-imidazole (1.81 g) dissolved in THF was added dropwise at -70°C and the mixture was stirred at -70°C for 1 hour. Compound 4 (5.54 g) dissolved in THF was added dropwise at -70°C and the mixture was stirred at -70°C for 1 hour. The mixture was brought till room temperature and it was stirred at room temperature overnight. Acetic acid (5 ml) was added and the mixture was stirred at room temperature for 20 minutes. K₂CO₃ (5 g) was added and the mixture was evaporated. The residue was taken up in water and DCM and the layers were separated. The aqueous layer was extracted with DCM. The combined organic layers were dried, filtered off and the solvent was evaporated, yielding 6.1 g (97%) of 6,11-dihydro- α -(1*H*-imidazol-2-yl)-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5*H*-imidazo[2,1-*b*][3]benzazepine-3-methanol (compound 46).


Tables F-1 to F-6 list the compounds that were prepared according to one of the above Examples and Table F-7 lists both the experimental (column heading "exp.") and theoretical (column heading "theor.") elemental analysis values for carbon, hydrogen and nitrogen of the compounds as prepared in the experimental part hereinabove.

Table F-1:







Co. No.	Ex. No.	A'	R ¹	R ²	-A-B-	Phys. Data (mp. in °C)
14	B.1	-(CH ₂) ₂ -	H	-CH ₃	-CH=CH-N(CH ₃)-	mp. 150
15	B.1	-CH ₂ -	H	H	-CH=CH-N(CH ₃)-	mp. 199.8
16	B.1	-(CH ₂) ₂ -	H	H	-CH=CH-N(CH ₃)-	mp. 179.5
17	B.1	-(CH ₂) ₂ -	H	H	-CH=CH-CF=CH-	mp. 190.2
18	B.1	-O(CH ₂) ₂ -	H	H	-CH=CH-N(CH ₃)-	mp. 174.4

Co. No.	Ex. No.	A ¹	R ¹	R ²	-A-B-	Phys. Data (mp. in °C)
19	B.1	-O(CH ₂) ₂ -	H	H	-CH=CH-CF=CH-	mp. 136.0
37	B.1	-COCH ₂ -	H	H	-CH=CH-N(CH ₃)-	mp. 220
38	B.12	-OCH ₂ CHOHCH ₂ -	H	H	-CH=CH-N(CH ₃)-	mp. 186.4
39	B.1	-(CH ₂) ₂ -	CH ₂ OH	H	-CH=CH-C(OCH ₃)=CH-	mp. 106.8

Table F-2 :




Co. No.	Ex. No.	A ¹	R ¹	R ²	Phys. Data (mp. in °C)
1	B.1	-(CH ₂) ₂ -	H	H	mp. 200.1
2	B.1	-(CH ₂) ₂ -	-CH ₂ OH	H	mp. 220.1
3	B.3	-(CH ₂) ₂ -	-CH ₂ OCOCH ₃	H	-
4	B.4	-(CH ₂) ₂ -	-CHO	H	mp. 193.5
5	B.5	-(CH ₂) ₂ -	-CH ₂ COOCH ₃	H	-
6	B.6	-(CH ₂) ₂ -	-COOCH ₃	H	mp. 179.3
40	B.6	-(CH ₂) ₂ -	-COOCH ₃	H	mp. 142.6; .HCl (1:1).H ₂ O(1:3)
41	B.6	-(CH ₂) ₂ -	-COOCH ₃	H	mp. 180.6; .HCl (1:2).H ₂ O(1:1)
42	B.6	-(CH ₂) ₂ -	-COOCH ₃	H	mp. 161.8; .(Z)-2-butene-dioate(1:1)
43	B.6	-(CH ₂) ₂ -	-COOCH ₃	H	mp. 166.0; .ethanedioate (1:1)
44	B.6	-(CH ₂) ₂ -	-COOCH ₃	H	.hydroxybutane-dioate (1:1)
45	B.6	-(CH ₂) ₂ -	-COOCH ₃	H	mp. 204.1; .HCl (1:3)
7	B.7	-(CH ₂) ₂ -	-COOH	H	mp. 174.2

Co. No.	Ex. No.	A ¹	R ¹	R ²	Phys. Data (mp. in °C)
8	B.1	-(CH ₂) ₂ -	-CH ₂ OH	-CH ₂ OH	mp. 183.3; .hemihydrate
9	B.9	-(CH ₂) ₂ -	-COOCH ₂ C ₆ H ₅	H	-
10	B.4	-(CH ₂) ₂ -	-CHO	-CHO	-
11	B.6	-(CH ₂) ₂ -	-COOCH ₃	-COOCH ₃	-
12	B.6	-(CH ₂) ₂ -	-COOC ₂ H ₅	H	-
13	B.1	-(CH ₂) ₂ -	Cl	H	-
20	B.1	-O(CH ₂) ₂ -	H	H	mp. 138.2
46	B.16	-(CH ₂) ₂ -		H	-
47	B.4	-(CH ₂) ₂ -		H	mp. 222.6
48	B.9	-(CH ₂) ₂ -	-COOC ₁₀ H ₂₁	H	-
49	B.9	-(CH ₂) ₂ -	-COOC ₁₂ H ₂₅	H	-
50	B.9	-(CH ₂) ₂ -		H	-
51	B.9	-(CH ₂) ₂ -		H	-
52	B.9	-(CH ₂) ₂ -		H	-
53	B.9	-(CH ₂) ₂ -	-COO(CH ₂) ₂ OC ₂ H ₅	H	-
54	B.9	-(CH ₂) ₂ -		H	-
55	B.9	-(CH ₂) ₂ -	-CONH ₂	H	-
56	B.9	-(CH ₂) ₂ -	-CON(CH ₃) ₂	H	-
57	B.10	-(CH ₂) ₂ -	-CH ₂ OH	Cl	mp. 211.3
58	B.10	-(CH ₂) ₂ -	Cl	Cl	mp. 191.1
59	B.10	-(CH ₂) ₂ -	Cl	-CH ₂ OH	-
60	B.4	-(CH ₂) ₂ -	Cl	-CHO	-
61	B.6	-(CH ₂) ₂ -	Cl	-COOC ₂ H ₅	mp. 173.8
62	B.11	-(CH ₂) ₂ -	-CH=CH-COOCH ₃	H	mp. 172.3
63	B.4	-(CH ₂) ₂ -	-CHO	Cl	mp. 208.4

Co. No.	Ex. No.	A ¹	R ¹	R ²	Phys. Data (mp. in °C)
64	B.1	-(CH ₂) ₂ -	H	-CH ₂ OH	mp. 149.0 ; .(E)-2-butenedioate (1:2)
65	B.9	-(CH ₂) ₂ -	-COO(CH ₂) ₃ CH ₃	H	mp. 130.3
66	B.1	-(CH ₂) ₂ -	H	-CH ₂ OH	-
67	B.4	-(CH ₂) ₂ -	H	-CHO	mp. 168.9
68	B.6	-(CH ₂) ₂ -	H	-COOCH ₃	mp. 209.9
69	B.6	-(CH ₂) ₂ -	-COOCH ₃	H	mp. 200 ; .(E)-2-butenedioate (2:3)
70	B.1	-CH ₂ -	-COOCH ₃	H	mp. 204.3
71	B.1	-COCH ₂ -	-COOCH ₃	H	mp. 152.3
72	B.13	-CO-	-COOCH ₃	H	mp. 139.7 ; .(E)-2-butenedioate (1:1)
73	B.12	-CH(OH)-CH ₂ -	-COOCH ₃	H	mp. 154.9
74	B.14	-C(=NOH)-CH ₂ -	-COOCH ₃	H	mp. 186.5
75	B.1	-(CH ₂) ₃ -	-COOCH ₃	H	mp. 156.7
76	B.6	-(CH ₂) ₂ -	-COOC ₂ H ₅	Cl	-
77	B.9	-(CH ₂) ₂ -	-COOCH(CH ₃) ₂	H	mp. 165.9
102	B.2	-CO(CH ₂) ₃ -	-CH ₂ OH	H	mp. 191.0

Table F-3




Co. No.	Ex. No.	A ¹	-A-B-	Z	Physical data (mp. in °C)
21	B.1	-O(CH ₂) ₂ -	-CH=CH-N(CH ₃)-	-(CH ₂) ₂ -	mp. 125.4
22	B.1	-O(CH ₂) ₂ -	-CH=CH-CF=CH-	-(CH ₂) ₂ -	mp. 135.6 mp. 180 ;
23	B.1	-(CH ₂) ₂ -	-CH=CH-CF=CH-	-(CH ₂) ₂ -	.(cyclohexyl)sulfamate (1:2) salt

-33-

Co. No.	Ex. No.	A ¹	-A-B-	Z	Physical data (mp. in °C)
24	B.1	-(CH ₂) ₂ -	-CH=CH-N(CH ₃)-	-(CH ₂) ₂ -	mp. 127.7
25	B.1	-(CH ₂) ₂ -	-CH=CH-S-	-CO-(CH ₂) [*] -	mp. 159.9
78	B.1	-(CH ₂) ₂ -	-CH=CH-CH=CH-	-O-(CH ₂) [*] -	mp. 176
79	B.1	-O(CH ₂) ₂ -	-CH=CH-CH=CH-	-O-(CH ₂) [*] -	mp. 189.8

* : the -CH₂- moiety is connected to the nitrogen of the imidazole ring

Table F-4 :



5


Co. No.	Ex. No.	R ^a	A ¹	==	-A-B-	Z	Physical data (mp. in °C)
26	B.1	H	-O(CH ₂) ₂ -	double	-CH=CH-S-	-CO-(CH ₂) [*] -	mp. 190.5; **
27	B.1	H	-(CH ₂) ₂ -	double	-CH=CH-S-	-CO-(CH ₂) [*] -	mp. 201.4
28	B.7	H	-(CH ₂) ₂ -	double	-CH=CH-S-	-CHOH-(CH ₂) [*] -	mp. 242.1
29	B.1	H	-(CH ₂) ₂ -	single	-CH=CH-N(CH ₃)-	-CO-(CH ₂) [*] -	mp. 200 ; **
30	B.1	H	-(CH ₂) ₂ -	double	-CH=CH-N(CH ₃)-	-CO-(CH ₂) [*] -	mp. 175.4
31	B.1	-CH ₃	-(CH ₂) ₂ -	double	-CH=CH-N(CH ₃)-	-(CH ₂) ₂ -	mp. 188.1
80	B.1	H	-(CH ₂) ₂ -	double	-CH=CH-CH=CH-	-(CH ₂) [*] -O-	mp. 170.7

* : the -CH₂- moiety is connected to the nitrogen of the imidazole ring

** : .(E)-2-butenedioate (2:3).ethanolate (1:1) salt form


Table F-5 :

10



Co. No.	Ex. No.	A ¹	R ¹	R ⁴	---	Z	Physical data
32	B.2	-CH ₂ -	H	-OCH ₃	double	-(CH ₂) ₂ -	mp. 214.8°C
33	B.2	-CH ₂ -	-CH ₂ OH	-OCH ₃	double	-(CH ₂) ₂ -	mp. 220.8°C
34	B.4	-CH ₂ -	-CHO	-OCH ₃	double	-(CH ₂) ₂ -	mp. 154°C
35	B.6	-CH ₂ -	-COOCH ₃	-OCH ₃	double	-(CH ₂) ₂ -	mp. 144.2°C
36	B.1	-(CH ₂) ₂	H	H	single	-CH ₂ -	mp. 169.2°C
81	B.1	-(CH ₂) ₂	-CH ₂ OH	H	single	-(CH ₂) ₂ -	mp. 179.3°C
82	B.4	-(CH ₂) ₂	-CHO	H	single	-(CH ₂) ₂ -	mp. 177.8°C
83	B.6	-(CH ₂) ₂	-COOCH ₃	H	single	-(CH ₂) ₂ -	mp. 158.3°C
84	B.1	-(CH ₂) ₂	H	H	double	-CH=CH-	mp. 160.5°C
85	B.2	-CH ₂ -	-COOCH ₃	Cl	double	-(CH ₂) ₂ -	mp. 164.0°C
86	B13	-CO-	-COOCH ₃	-CH ₃	double	-(CH ₂) ₂ -	mp. 131.2°C

Table F-6:



Co. No.	Ex. No.	Q-A ²	- A ¹ -	Physical data
87	B.1		-CH ₂ CH ₂ -	-
88	B.1	phenylmethyl	-CH ₂ CH ₂ -	-
89	B.1	2-pyridinylmethyl	-CH ₂ CH ₂ -	-
90	B15	phenyl	-CH ₂ -	-
91	B.1		-CH ₂ CH ₂ -	-
92	B.1		-CH ₂ CH ₂ -	-
93	B.1	3,5-bis(trifluoromethyl)phenylmethyl	-CH ₂ CH ₂ -	-

-35-



Co. No.	Ex. No.	Q-A ²	- A ¹ -	Physical data
94	B.1		-CH ₂ CH ₂ -	mp. 190.6°C
95	B.1	6-chloro-2-pyridinyl	-CH ₂ CH ₂ -	mp. 139.1°C
96	B.1	4-chlorophenylmethyl	-CH ₂ CH ₂ -	mp. 171.2°C
97	B.1	4-methoxyphenylmethyl	-CH ₂ CH ₂ -	mp. 174.8°C
98	B.1	 (CH ₂) ₄ -	-CH ₂ CH ₂ -	mp. 193.5°C; .(E)-2-butenedioate
99	B.1	3,5-difluorophenylmethyl	-CH ₂ CH ₂ -	mp. 117.2°C
100	B.15	phenyl	-CH ₂ CH ₂ -	mp. 132.3°C
101	B.1	2-quinolinylmethyl	-CH ₂ O(CH ₂) ₂ -	mp. 125.0
103	B.1	3,5-dimethylphenylmethyl	-CH ₂ CH ₂ -	mp. 123.1

Table F-7 :

Comp. No.	Carbon		Hydrogen		Nitrogen	
	Exp.	Theor.	Exp.	Theor.	Exp.	Theor.
3	76.00	76.23	6.42	6.40	9.30	9.36
5	75.28	76.23	6.35	6.40	9.18	9.36
9	78.08	78.16	5.97	6.10	8.44	8.48
11	72.77	72.88	5.76	5.96	8.71	8.72
12	76.12	76.23	6.33	6.40	9.41	9.36
13	74.81	74.92	5.78	5.93	9.88	9.98
76	72.62	72.08	6.09	5.89	8.84	8.85
87	78.24	78.19	6.31	6.39	6.85	7.20
88	76.32	76.52	6.63	6.61	7.73	7.87
89	74.02	74.13	6.45	6.41	10.50	10.48
90	76.22	76.02	6.35	6.18	8.35	8.31
91	78.85	78.19	6.42	6.39	7.10	7.20
92	77.57	76.76	6.86	6.81	7.62	7.67
93	65.05	64.57	5.14	4.97	6.14	6.27

5

RECTIFIED SHEET (RULE 91)
ISA/EP

C. Pharmacological examples

Example C.1

The *in vitro* effectiveness of a compound of formula (I) as a MDR modulator was assessed using a human multidrug resistant cancer cell line (Park J.-G. et al., *J. Natl. Cancer Inst.*, 86:700 - 705 (1994) and Hill B.T. et al., *Cancer Chemother. Pharmacol.*, 33:317 - 324 (1994)). Briefly, the cell growth of K562/C1000, a human multidrug resistant cancer cell line, was measured in the presence of a full range of concentrations (ranging from 10^{-12} to 10^{-5} M) of a classic cytostatic, e.g. vinblastine. The $IC_{50(\text{cytostatic})}$, i.e. the concentration of the cytostatic needed to reduce cell growth by 50%, was measured. Also, the growth of K562/C1000 was measured in the presence of a full range of concentrations of a classic cytostatic and a fixed concentration (10^{-6} M) of a MDR modulating compound, yielding $IC_{50(\text{cytostatic/compound})}$. The sensitization ratio 'SR' is determined as the ratio of $IC_{50(\text{cytostatic})}$ over $IC_{50(\text{cytostatic/compound})}$. Compounds 1, 3, 4, 6, 9, 11 - 13, 18, 20, 27, 30 - 36, 47, 45, 58, 61 - 63, 65, 67, 69, 70, 73, 74, 75, 77, 82, 84, 87 - 89 and 91 - 101 as listed in Tables F-1 to F-6 have a SR value greater or equal than 5. Compounds 2, 5, 8, 14, 15, 19, 19, 22, 23 - 25, 26, 29, 33, 37, 38, 48, 52, 55 - 57, 64, 68, 71, 76, 78, 79, 80 and 85 as listed in Tables F-1 to F-6 have a SR value between 1 and 5.

Example C.2

The potential of compounds of formula (I) to reverse multidrug resistance can be demonstrated by the ability of compounds of formula (I) to reverse the adriamycine resistance in the P388/ADR (adriamycine resistance cell line) murine leukemia *in vivo*.

Male B6D2F1 mice (18 - 21 g) were injected intraperitoneally with 1×10^5 P388/ADR cells at day 0. Daily intraperitoneal treatment with adriamycine, a test compound of formula (I) or a combination of both was installed from day 1 until day 10. Control animals received the vehicle (15% 4-OH-propyl- β -cyclodextrine in saline). Each group consisted of 8 animals. Adriamycine was dosed at a concentration of 1.25 mg/kg body weight, half the maximal tolerable dose of adriamycine in this treatment schedule. The test compound was dosed at 20, 10, 5, 2.5, 1.25 and 0.63 mg/kg either as single treatment or combined with adriamycine.

Survival of the animals was recorded each day and expressed as a percentage of the median survival in the treated groups compared to the median survival in the control group, the latter to be said to be 100%.

Table C-1 lists the effect of compound 6 and adriamycine on the survival of mice injected with P388/ADR leukemia.

- doses of compound 6 and adriamycine are expressed as mg/kg body weight.
- the column "Survival Days" give the median day of death after inoculation of 1×10^5 P388/ADR cells at day 0, with the minimum and maximum number of days shown in parantheses
- the column "MST%" shows the median percentage of the treated groups compared to the median survival in the control group, the latter be said to be 100%
- column "% Change vs. ADR" give the difference in MST% of the different groups compared to the MST% in the adriamycine-mono-therapy group.

Table C-1 :

Compound 6 (mg/kg)	Adriamycine (mg/kg)	Survival Days med(min- max)	MST%	% Change vs. ADR
0	0	11(10-14)	100	-18
0	1.25	13(12-15)	118	0
20	0	11(10-14)	100	-18
10	0	10.5(10-13)	95	-23
5	0	11(10-13)	100	-18
2.5	0	10.5(10-12)	95	-23
1.25	0	11.5(10-16)	105	-13
0.63	0	11(10-12)	100	-18
20	1.25	15.5(14-17)	141	23
10	1.25	15(14-28)	136	18
5	1.25	14.5(11-16)	132	14
2.5	1.25	14.5(10-20)	132	14
1.25	1.25	15(14-17)	136	18
0.63	1.25	14.5(14->30)	132	14

- 15 Table C-1 illustrated that the group treated with a combination of compound 6 and adriamycine have a Median Survival Time (MST) which is 14 to 23% longer than the adriamycine mono-therapy group.

D. Composition examples

The following formulations exemplify typical pharmaceutical compositions in dosage unit form suitable for systemic or topical administration to warm-blooded animals in accordance with the present invention.

5

"Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I), a *N*-oxide form, a pharmaceutically acceptable acid or base addition salt or a stereochemically isomeric form thereof.

10 Example D.1 : Oral solutions

9 g of methyl 4-hydroxybenzoate and 1 g of propyl 4-hydroxybenzoate are dissolved in 4 l of boiling purified water. In 3 l of this solution are dissolved first 10 g of 2,3-dihydroxybutanedioic acid and thereafter 20 g of the A.I. The latter solution is combined with the remaining part of the former solution and 12 l of 1,2,3-propanetriol and 3 l of sorbitol 70% solution are added thereto. 40 g of sodium saccharin are dissolved in 0.5 l of water and 2 ml of raspberry and 2 ml of gooseberry essence are added. The latter solution is combined with the former, water is added q.s. to a volume of 20 l providing an oral solution comprising 5 mg of the A.I. per teaspoonful (5 ml). The resulting solution is filled in suitable containers.

20

Example D.2 : Capsules

20 g of the A.I., 6 g sodium lauryl sulfate, 56 g starch, 56 g lactose, 0.8 g colloidal silicon dioxide, and 1.2 g magnesium stearate are vigorously stirred together. The resulting mixture is subsequently filled into 1000 suitable hardened gelatin capsules, each comprising 20 mg of the A.I..

25

Example D.3 : Film-coated tablets

Preparation of tablet core

A mixture of 100 g of the A.I., 570 g lactose and 200 g starch is mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and 10 g polyvinylpyrrolidone in about 200 ml of water. The wet powder mixture is sieved, dried and sieved again. Then there are added 100 g microcrystalline cellulose and 15 g hydrogenated vegetable oil. The whole is mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient.

30

35 Coating

To a solution of 10 g methyl cellulose in 75 ml of denaturated ethanol there is added a solution of 5 g of ethyl cellulose in 150 ml of dichloromethane. Then there are added

75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 g of polyethylene glycol is molten and dissolved in 75 ml of dichloromethane. The latter solution is added to the former and then there are added 2.5 g of magnesium octadecanoate, 5 g of polyvinylpyrrolidone and 30 ml of concentrated colour suspension and the whole is homogenated. The tablet cores are coated with the thus obtained mixture in a coating apparatus.

Example D.4 : Injectable solution


1.8 g methyl 4-hydroxybenzoate and 0.2 g propyl 4-hydroxybenzoate were dissolved in about 0.5 l of boiling water for injection. After cooling to about 50°C there were added while stirring 4 g lactic acid, 0.05 g propylene glycol and 4 g of the A.I. The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 l volume, giving a solution of 4 mg/ml of A.I. The solution was sterilized by filtration and filled in sterile containers.

Example D.5 : Suppositories

3 Grams A.I. was dissolved in a solution of 3 grams 2,3-dihydroxybutanedioic acid in 25 ml polyethylene glycol 400. 12 Grams surfactant and 300 grams triglycerides were molten together. The latter mixture was mixed well with the former solution. The thus obtained mixture was poured into moulds at a temperature of 37-38°C to form 100 suppositories each containing 30 mg/ml of the A.I.

Claims

1. A compound of formula (I)



5

a *N*-oxide form, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein

the dotted line is an optional bond;

10

n is 1 or 2;

*R*¹ is hydrogen; halo; formyl; C₁₋₄alkyl; C₁₋₄alkyl substituted with 1 or 2 substituents each independently selected from hydroxy, C₁₋₄alkyloxy, C₁₋₄alkylcarbonyloxy, imidazolyl, thiazolyl or oxazolyl; or a radical of formula

15

-X-CO-OR⁵ (a-1);

-X-CO-NR⁶R⁷ (a-2); or

-X-CO-R¹⁰ (a-3);

wherein -X- is a direct bond, C₁₋₄alkanediyl or C₂₋₆alkenediyl;

*R*⁵ is hydrogen; C₁₋₁₂alkyl; Ar; Het; C₁₋₆alkyl substituted with C₁₋₄alkyloxy, C₁₋₄alkyloxycarbonyl, C₁₋₄alkyloxy, Ar or Het;

20

*R*⁶ and *R*⁷ each independently are hydrogen or C₁₋₄alkyl;

*R*¹⁰ is imidazolyl, thiazolyl or oxazolyl;

*R*² is hydrogen, halo, C₁₋₄alkyl, hydroxyc₁₋₄alkyl, C₁₋₄alkyloxycarbonyl, carboxyl, formyl or phenyl;

25

*R*³ is hydrogen, C₁₋₄alkyl or C₁₋₄alkyloxy;

*R*⁴ is hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkyloxy or haloC₁₋₄alkyl;

Z is *Z*¹ or *Z*²;

wherein *Z*¹ is a bivalent radical of formula -CH₂-, -CH₂-CH₂- or -CH=CH-; provided that when the dotted line is a bond, then *Z*¹ is other than -CH₂-;

30

*Z*² is a bivalent radical of formula -CHOH-CH₂-, -O-CH₂-, -C(=O)-CH₂- or -C(=NOH)-CH₂-;

-41-

-A-B- is a bivalent radical of formula

-Y-CR⁸=CH- (b-1);

-CH=CR⁸-Y- (b-2);

-CH=CR⁸-CH=CH- (b-3);

5 -CH=CH-CR⁸=CH- (b-4); or

-CH=CH-CH=CR⁸- (b-5);

wherein each R⁸ independently is hydrogen, halo, C₁₋₄alkyl, C₁₋₄alkyloxy, hydroxyC₁₋₄alkyl, hydroxycarbonylC₁₋₄alkyl, formyl, carboxyl, ethenyl substituted with carboxyl, or ethenyl substituted with C₁₋₄alkyloxycarbonyl;

each Y independently is a bivalent radical of formula -O-, -S- or -NR⁹-; wherein R⁹ is hydrogen, C₁₋₄alkyl or C₁₋₄alkylcarbonyl;

-A¹- is a direct bond; C₁₋₆alkanediyl; C₁₋₆alkanediyl-oxy-C₁₋₆alkanediyl; C₁₋₆alkanediylloxy; carbonyl; C₁₋₆alkanediylcarbonyl; C₁₋₆alkanediylloxy substituted with hydroxy; or C₁₋₆alkanediyl substituted with hydroxy or =NOH;

-A²- is a direct bond or C₁₋₆alkanediyl;

Q is phenyl; phenyl substituted with one or two substituents selected from hydrogen, halo, hydroxy, C₁₋₄alkyl, C₁₋₄alkyloxy or haloC₁₋₄alkyl; naphthalenyl; naphthalenyl substituted with one or two substituents selected from hydrogen, halo, hydroxy, C₁₋₄alkyl, C₁₋₄alkyloxy or haloC₁₋₄alkyl; pyridinyl; pyridinyl substituted with one or two substituents selected from hydrogen, halo, hydroxy, C₁₋₄alkyl, C₁₋₄alkyloxy or haloC₁₋₄alkyl; quinolinyl; or quinolinyl substituted with one or two substituents selected from hydrogen, halo, hydroxy, C₁₋₄alkyl, C₁₋₄alkyloxy or haloC₁₋₄alkyl;

Ar is phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from hydrogen, halo, C₁₋₄alkyl or C₁₋₄alkyloxy;


Het is furanyl; furanyl substituted with C₁₋₄alkyl, C₁₋₄alkyloxy or hydroxyC₁₋₄alkyl; oxazolyl; oxazolyl substituted with C₁₋₄alkyl or C₁₋₄alkyloxy; or quinolinyl.

2. A compound according to claim 1 wherein -A-B- is a bivalent radical of formula (b-2), (b-3) or (b-4); Z is Z¹ wherein Z¹ is a bivalent radical of formula -CH₂-CH₂- or -CH₂-, or Z is Z² wherein Z² is a bivalent radical of formula -C(=O)-CH₂-; -A¹- is C₁₋₆alkanediyl, C₁₋₆alkanediylloxy, carbonyl, C₁₋₆alkanediylloxy substituted with hydroxy, or C₁₋₆alkanediyl substituted with hydroxy; -A²- is a direct bond or C₁₋₆alkanediyl; Q is phenyl, naphthalenyl, pyridinyl, quinolinyl, phenyl substituted

- with halo or C₁₋₆alkyloxy, naphthalenyl substituted with halo or C₁₋₆alkyloxy, pyridinyl substituted with halo or C₁₋₆alkyloxy or quinolinyl substituted with halo or C₁₋₆alkyloxy; R¹ is hydrogen, halo, formyl, C₁₋₄alkyl substituted with hydroxy, or a radical of formula (a-1) wherein X is a direct bond or C₁₋₄alkanediyl and R⁵ is hydrogen, C₁₋₁₂alkyl, Ar or C₁₋₆alkyl substituted with Het; R² is hydrogen, halo, C₁₋₄alkyl, formyl, hydroxyC₁₋₄alkyl or C₁₋₄alkyloxycarbonyl; R³ is hydrogen; R⁴ is hydrogen, halo, C₁₋₆alkyl or C₁₋₆alkyloxy and the dotted line is a bond.
3. A compound according to any of claims 1 to 2 wherein Z is -CH₂-CH₂-; -A-B- is -CH=CH-CH=CH-; -A¹- is -CH₂-CH₂-, -CH₂-CH₂-CH₂- or -O-CH₂-CH₂-; -A²- is -CH₂-; R¹ is hydrogen, halo, formyl or a radical of formula (a-1) wherein X is a direct bond and R⁵ is hydrogen, C₁₋₁₂alkyl, Ar or C₁₋₆alkyl substituted with Het; R² is hydrogen, C₁₋₄alkyl, formyl or C₁₋₄alkyloxycarbonyl; R³ is hydrogen; R⁴ is hydrogen or C₁₋₄alkyloxy and the dotted line is a bond.
4. A compound according to claim 1 wherein the compound is methyl 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate; or dimethyl 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-2,3-dicarboxylate; or ethyl 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate; methyl 11-[1-[[3,5-dimethoxy-4-(2-quinolinylmethoxy)phenyl]methyl]-4-piperidinylidene]-6,11-dihydro-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate; methyl 6,11-dihydro-11-[1-[3-[4-(2-quinolinylmethoxy)phenyl]propyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate; methyl 6,11-dihydro-11-[1-[2-[4-(2-naphthalenylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate; methyl 6,11-dihydro-11-[1-[2-[4-(phenylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate; and methyl 6,11-dihydro-11-[1-[2-[4-(1-naphthalenylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate; the stereoisomeric forms and the pharmaceutically acceptable addition salts thereof.

-43-

5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as described in any one of claims 1 to 4.
- 5 6. A process for preparing a pharmaceutical composition as claimed in claim 5 characterized in that a therapeutically active amount of a compound as claimed in any one of claims 1 to 4 is intimately mixed with a pharmaceutically acceptable carrier.
- 10 7. A compound according to any one of claims 1 to 4 for use as a medicine.
8. A product containing
 - a) a composition comprising a pharmaceutically effective amount of a compound according to any of claims 1 to 4 and a pharmaceutically acceptable carrier; and
 - 15 b) a composition comprising a pharmaceutically effective amount of an anti-neoplastic agent and a pharmaceutically acceptable carrier, as a combined preparation for simultaneous, separate or sequential use in anti-neoplastic therapy.
- 20 9. A product containing
 - a) a composition comprising a pharmaceutically effective amount of a compound according to any of claims 1 to 4 and a pharmaceutically acceptable carrier;
 - b) and a composition comprising a pharmaceutically effective amount of a pharmaceutical agent useful to treat conditions caused by pathogens and a pharmaceutically acceptable carrier, as a combined preparation for
 - 25 simultaneous, separate or sequential use in the treatment of conditions caused by pathogens.
- 30 10. A compound of formula (II-b)



a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof wherein

35 n is 1 or 2;

R^4 is hydrogen, halo, C_{1-4} alkyl, C_{1-4} alkyloxy or halo C_{1-4} alkyl;

Q^1 is phenyl substituted with one or two substituents selected from hydrogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkyloxy or halo C_{1-4} alkyl; naphthalenyl; naphthalenyl substituted with one or two substituents selected from hydrogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkyloxy or halo C_{1-4} alkyl; pyridinyl; pyridinyl substituted with one or two substituents selected from hydrogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkyloxy or halo C_{1-4} alkyl; quinolinyl; or quinolinyl substituted with one or two substituents selected from hydrogen, hydroxy, C_{1-4} alkyl, C_{1-4} alkyloxy or halo C_{1-4} alkyl;


$-A^1-$ is C_{1-6} alkanediyl, C_{1-6} alkanediyoxy or C_{1-6} alkanediyoxy C_{1-6} alkanediyl;

$-A^2-$ is a direct bond or C_{1-6} alkanediyl; and


W is halo, methanesulfonyloxy or benzenesulfonyloxy.

11. A process for preparing a compound of formula (I) characterized by

a) reacting a reagent of formula (III), wherein T represents the fused imidazole moiety,




with an intermediate of formula (II), wherein W represents an appropriate leaving group:




b) O-alkylating an intermediate of formula (IV), wherein W represents an appropriate leaving group, with a reagent of formula (V);


-45-




- 5 c) reductively *N*-alkylating in intermediate of formula (III) with an intermediate of formula (XIX), wherein A^{1'} represents a direct bond, C₁₋₅alkanediyl, C₁₋₅alkanediyl-oxy or a C₁₋₆alkanediyl-oxyC₁₋₅alkanediyl moiety, thereby yielding compounds of formula (I-i) wherein -A^{1'}- represents C₁₋₆alkanediyl, C₁₋₆alkanediyl-oxy or C₁₋₆alkanediyl-oxyC₁₋₆alkanediyl;



- 10 d) converting a compound of formula (I-a), wherein M represents the substituted piperidine moiety,




15 into a compound of formula (I-b), according to art-known esterification methods.




-46-

- e) reacting a compound of formula (I-a-1) with an oxidizing agent in a reaction-inert solvent;



5

- f) esterification of compound of formula (I-d) to a compound of formula (I-e);




10

- g) hydrolyzing a compound of formula (I-e) to a compound of formula (I-d) in the presence of an acid or a base;


- h) reacting a compound of formula (I-c) with methyl methylthiomethyl sulfoxide in a suitable solvent, thus yielding a compound of formula (I-f);

15




-47-

- i) reacting a compound of formula (I-c) with an alcohol of formula R^5OH in the presence of acetic acid, MnO_2 and $NaCN$, thus yielding a compound of formula (I-e-1);




- j) reacting a compound of formula (I-g) with a reducing agent in a reaction-inert solvent;



wherein in the above reaction schemes the radicals R^1 , R^2 , R^3 , R^4 , Z , $-A-B-$, A^1 , A^2 and Q are as defined in claim 1 and W is an appropriate leaving group;

or, converting compounds of formula (I) into each other following art-known transformation reactions; and further, if desired, converting the compounds of formula (I), into an acid addition salt by treatment with an acid, or into a base addition salt by treatment with a base, or conversely, converting the acid addition salt form into the free base by treatment with alkali, or converting the base addition salt into the free acid by treatment with acid; and, if desired, preparing *N*-oxide and/or stereochemically isomeric forms thereof.

12. A process for preparing a compound as claimed in claim 10 wherein an intermediate of formula (VI) is *O*-alkylated with an intermediate of formula (IV), in a reaction-inert solvent and subsequently the hydroxy group of an intermediate of formula (VII) is converted into a leaving group W;



in the above reaction scheme n , R^4 , Q^1 , $A^{1'}$, A^2 and W are as defined in claim 10 and W^1 is an appropriate leaving group;

or an intermediate compound of formula (II-a) is converted into an acid addition salt, or conversely, an acid addition salt is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/01264

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D487/04 A61K31/55 C07D495/14 C07D487/14 C07D498/04
C07D471/04 C07D491/147 //(C07D487/04,235:00,223:00),
(C07D495/14,333:00,235:00,223:00),(C07D487/14,235:00,223:00,

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 16044 A (MERRELL DOW) 19 August 1993 see claims 1,11 ---	1,5
A	WO 94 22842 A (BASF) 13 October 1994 see page 1, line 34 - line 37; claim 1 ---	1,5
A	CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 30, no. 5, 1992, BERLIN (DE), pages 165-173, XP000196690 A. RAMU ET AL.: "Reversal of multidrug resistance by phenothiazines and structurally related compounds" see table I -----	1,5

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

d document member of the same patent family

Date of the actual completion of the international search

10 June 1997

Date of mailing of the international search report

20.06.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

Intc. nal Application No
PCT/EP94/01264

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 209:00), (C07D498/04, 267:00, 235:00)		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<div style="display: flex; justify-content: space-between;"> <input type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex. </div>		
<div style="display: flex;"> <div style="flex: 1;"> <p>* Special categories of cited documents :</p> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p> document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*U* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*A* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search		Date of mailing of the international search report
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+ 31-70) 340-3016		Authorized officer

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/01264

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9316044 A	19-08-93	AU 662602 B	07-09-95
		AU 3484293 A	03-09-93
		CA 2129144 A	19-08-93
		EP 0643693 A	22-03-95
		HU 70564 A	30-10-95
		JP 7503957 T	27-04-95
		NO 942920 A	05-08-94

WO 9422842 A	13-10-94	CA 2155759 A	13-10-94
		EP 0691962 A	17-01-96
		JP 8508270 T	03-09-96
		US 5622953 A	22-04-97

THIS PAGE BLANK (USPTO)